Developing Story: Beyond Camizestrant — The Evolving Landscape of ER+/HER2- MBC with Dr. Sarah Premji
The oral SERD era has arrived, and the treatment landscape for HR+/HER2- metastatic breast cancer is changing fast. Hosts Victoria Goldberg and Abigail Johnston sit down with Dr. Sarah Premji of Sarah Cannon to map out what has shifted beyond SERENA-6, from new FDA approvals and emerging mechanisms to real-world sequencing decisions and the latest trial data. If you are trying to make sense of a rapidly evolving algorithm, this episode is for you.
Developing Story: The Camizestrant Vote, Doctors Weigh In with Dr. Sarah Sammons & Dr. Neil Vasan
When the ODAC voted 6–3 against the camizestrant strategy, the headlines told you what happened — this episode tells you why. We're back for round two with Dr. Sarah Sammons, newly appointed Co-Leader of Breast Oncology at the University of Maryland Greenebaum Comprehensive Cancer Center, and Dr. Neil Vasan, Acting Chair of the ODAC and Director of Translational Research in Breast Cancer at NYU Langone Health, who sat in that room and cast one of the three yes votes. Alongside patient advocates Janice Cowden and Abigail Johnston, we break down the four FDA critiques that drove the vote, what the quality of life data showed and why regulators couldn't act on it, and what the FDA's new August 14th review deadline means for patients. Plus: why this science isn't going anywhere, and what ctDNA-guided treatment could look like in the very near future.
Developing Story: The Camizestrant Vote — When Your Blood Test Knows Before Your Scan Does
Six MBC patient advocates join host Victoria Goldberg to break down the FDA advisory committee's vote on camizestrant and the SERENA-6 trial. The panel unpacks what the vote really means, whether the science of molecular progression is ready for clinical practice, and why patient advocates need a seat at the table before trials are designed.
Front Row Seat: Dr. Fatima Cardoso on Aiming Higher - Hope and the Road to a Cure
For decades, metastatic breast cancer meant one thing: managing the disease. But a new global report — and a bold new charter — say it's time to aim higher. Host Victoria Goldberg sits down with Dr. Fátima Cardoso of the ABC Global Alliance to examine 10 years of hard-won progress, confront the inequalities that have grown worse, and explore why, for the first time, the word cure is entering the conversation.
Front Row Seat: Can We Talk about the Cure? A Conversation with Dr. Eric Winer
For decades, stage IV meant managing the disease — not beating it. That story is beginning to change.
In this episode of Live from Stage IV, Victoria Goldberg sits down with Dr. Eric Winer — oncologist, director of the Yale Cancer Center, and former president of ASCO — to ask a question that once felt impossible: Can we cure metastatic breast cancer?
Dr. Winer walks through the landmark trials reshaping HER2-positive treatment, introduces the concept of "curative hope," and gets into what's hardest about ER-positive and triple-negative disease, cancer dormancy, the science of exercise, and bold new trial designs like SAFFO and HORIZON that are rewriting the playbook.